NOXXON Receives Research Grant from the Federal Ministry of Education and Research

BERLIN--(BUSINESS WIRE)--NOXXON announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF). NOXXON will receive approximately one million Euro in research funding under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies. The program is dedicated to further strengthen and broaden NOXXON’s drug discovery platform to identify innovative medicines based on mirror-image oligonucleotides (Spiegelmers®). NOXXON’s Chief Scientific Officer Dr. Sven Klussmann commented: “We are delighted that the government has decided to reward NOXXON’s excellent research. The funding will be beneficial in supporting the development and growth of existing and new technologies.”

About NOXXON Pharma AG:

Based on one of the biggest and best protected patent portfolios in the industry, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: http://www.noxxon.net